The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
118756313 11875631 3 F 20151211 20160808 20151229 20160818 EXP JP-PFIZER INC-2015470090 PFIZER 84.00 YR F Y 48.00000 KG 20160818 MD JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
118756313 11875631 1 PS ZOSYN PIPERACILLIN SODIUMTAZOBACTAM SODIUM 1 Intravenous drip 4.5 G, 2X/DAY 63 G 50684 4.5 G BID
118756313 11875631 2 SS ZOSYN PIPERACILLIN SODIUMTAZOBACTAM SODIUM 1 Intravenous drip 4.5 G, 3X/DAY 63 G 50684 4.5 G TID
118756313 11875631 3 SS ZOSYN PIPERACILLIN SODIUMTAZOBACTAM SODIUM 1 63 G 50684
118756313 11875631 4 C METILON METAMIZOLE SODIUM 1 Intramuscular 1 ML, DAILY 0 1 ML
118756313 11875631 5 C METILON METAMIZOLE SODIUM 1 0
118756313 11875631 6 C FAMOTIDINE. FAMOTIDINE 1 Intravenous drip 40 MG, DAILY 0 40 MG
118756313 11875631 7 C NEOLAMIN MULTI V HYDROXOCOBALAMINPYRIDOXINE HYDROCHLORIDETHIAMINE HYDROCHLORIDE 1 Intravenous drip 1 V/DAY 0
118756313 11875631 8 C PARESAFE 2 Intravenous drip 500 ML, 1X/DAY 0 500 ML QD
118756313 11875631 9 C NORVASC AMLODIPINE BESYLATE 1 Oral 5 MG, 1X/DAY 0 5 MG QD
118756313 11875631 10 C NIZORAL KETOCONAZOLE 1 Topical UNK 0
118756313 11875631 11 C NEOAMIYU AMINO ACIDS 1 Intravenous drip 200 MG, 1X/DAY 0 200 MG
118756313 11875631 12 C PN TWIN 2 Intravenous drip 1200 ML, 1X/DAY 0 1200 ML QD
118756313 11875631 13 C MINERIC 5 2 Intravenous drip 1 ML, 1X/DAY 0 1 ML QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
118756313 11875631 1 Pneumonia aspiration
118756313 11875631 2 Pyrexia
118756313 11875631 3 C-reactive protein increased
118756313 11875631 4 Pyrexia
118756313 11875631 5 C-reactive protein increased
118756313 11875631 6 Prophylaxis against gastrointestinal ulcer
118756313 11875631 7 Nutritional supplementation
118756313 11875631 8 Nutritional supplementation
118756313 11875631 9 Hypertension
118756313 11875631 10 Fungal skin infection
118756313 11875631 11 Nutritional supplementation
118756313 11875631 12 Nutritional supplementation
118756313 11875631 13 Nutritional supplementation

Outcome of event

Event ID CASEID OUTC COD
118756313 11875631 DE
118756313 11875631 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
118756313 11875631 Multiple organ dysfunction syndrome
118756313 11875631 Renal failure

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
118756313 11875631 1 20151205 20151205 0
118756313 11875631 2 20151206 20151209 0
118756313 11875631 4 20151204 20151205 0
118756313 11875631 6 20151102 20151211 0
118756313 11875631 7 20151103 20151211 0
118756313 11875631 8 20151002 20151211 0
118756313 11875631 9 20151112 20151202 0
118756313 11875631 10 20151208 0
118756313 11875631 11 20151211 20151211 0
118756313 11875631 12 20151103 20151211 0
118756313 11875631 13 20151103 20151211 0